In order to support and accelerate vaccine development in Europe, the TRANSVAC project is providing a vaccine development platform offering a set of coordinated vaccine R&D facilities and services accessible to external users.

Through a peer-reviewed competitive process, European groups may apply to benefit from the expertise, reagents, and facilities of the TRANSVAC project free of charge. They are not restricted to any disease in particular. Only European user groups (from EU Members states or Associated states) can apply and only to TRANSVAC service infrastructures outside their own country.

Researchers not eligible for free access are able to access the Services at their own cost.

I. Adjuvants  

Vaccine formulation laboratory - World Health Organization Collaborating Centre - University of Lausanne, Switzerland

II. Vaccine preclinical testing platform

In-vivo non-human primate models:

a) Experimental non-human primate model facility, Biomedical Primate Research Centre, The Netherlands - THIS SERVICE IS ONLY AVAILABLE via paid access. Funding capacity for free services is exhausted.  

b) Immunocompromised rhesus macaque models - Health Protection Agency, Centre for Emergency Preparedness and Response, United Kingdom

Experimental murine validation platform - Helmholtz Centre for Infection Research, Germany

Large Animal studies (pigs)- Central Veterinary Institute of Wageningen UR (former partner: ID-Lelystad, Animal Sciences Group of Wageningen UR), The Netherlands

III. Global analyses platform

ILLUMINA Deep sequencing - Helmholtz Centre for Infection Research, Germany

AGILENT Microarrays - Max Planck Institute for Infection Biology, Germany

AFFYMETRIX Microarrays - University of Regensburg, Germany

IV. Stable assay and reference reagent standards platform

Stable reference reagents for vaccine studies - Heath Protection Agency - National Institute for Biological Standards and Control, United Kingdom